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SUMMARY
In clinical decision making, it is common to ask whether, and how much, a
diagnostic procedure is contributing to subsequent treatment decisions. Statistically, quantification of the value of the information provided by a diagnostic procedure can be carried out using decision trees with multiple decision
points, representing both the diagnostic test and the subsequent treatments
that may depend on the test’s results. This article investigates probabilistic
sensitivity analysis approaches for exploring and communicating parameter
uncertainty in such decision trees. Complexities arise because uncertainty
about a model’s inputs determines uncertainty about optimal decisions at
all decision nodes of a tree. We present the expected utility solution strategy for multistage decision problems in the presence of uncertainty on input
parameters, propose a set of graphical displays and summarization tools for
probabilistic sensitivity analysis in multistage decision trees, and provide an
application to axillary lymph node dissection in breast cancer.
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1

INTRODUCTION

Assessing uncertainty about decision models is emerging as a critical component of sound medical decision making. Probabilistic sensitivity analysis
(PSA) provides a practical, flexible, and well founded approach for representing uncertainty about model inputs and for exploring its implications (1;
2; 3; 4). Monte Carlo simulation permits implementation of PSA in complex
multiparameter models, while accommodating for nonstandard distributions
and dependence among input parameters. PSA can be linked to statistical
inference procedures, for example by using output from Markov Chain Monte
Carlo exploration of posterior distributions (5) as the input of a PSA (6), or
via frequentist resampling techniques (7).
With rare exceptions (8), investigation of PSA in decision trees has focused on trees including a single, although possibly multi–branched, decision
node. This paper presents tools for probabilistic sensitivity analysis in multistage decision problems, that is problems in which several decisions are
made at different points in time, on the basis of different information. An
important example in medicine is deciding whether to perform a diagnostic
or staging procedure to support subsequent treatment decisions.
In multistage problems, the decision about whether or not to gather certain information has impact on the overall utility via its effect of future
decisions. The worthiness of the information can then be quantified by comparing the expected utility of the optimal solutions with and without it (9;
10; 11; 12; 8). The standard version of this quantification, also called “value
of information” analysis, relies on knowing with certainty the optimal deci-
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sion functions downstream. Uncertainty about model inputs, however, determines uncertainty about optimal decisions at all stages of a multistage
problem. Because of this, in a PSA of the value of diagnostic information
it is important separately to quantify and convey the uncertainty deriving
directly from randomness in the input, and the uncertainty deriving from
randomness in the optimal future decisions. In clinical settings, this distinction becomes critical, as will be seen, because it has implication for the
appropriateness of a treatment.
This article is motivated by the controversy surrounding axillary lymph
node dissection (ALND), or the surgical removal of the axillary lymph nodes,
a common procedure in early breast cancer patients. ALND is routinely
performed as part of a mastectomy, but it is elective in breast conservation
patients, for whom it is a distinct procedure from the main surgery. It is used
primarily to guide the choice of systemic adjuvant therapy, to provide local
control of cancer and to give patients prognostic information for personal
use. ALND results in morbidity and minor but permanent problems (13)
and requires a significant use of resources (14).
Recent randomized trials have questioned the long held belief that the
relative benefits of hormonal versus cytotoxic adjuvant therapies depend on
nodal status (15; 16). The prognostic information conveyed by the results of
an ALND, however, may still be useful in decision making, as a patient with
a worse prognosis may be more inclined to undergo a more aggressive form
of treatment. The role of ALND in local control is also in question. Axillary
irradiation (XRT) appears to provide comparable local control and survival
benefits in patients with clinically uninvolved lymph nodes (17).
4
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This complex scenario has led to disagreement on the routine use of ALND
(18; 19; 20; 21; 22), and encouraged the use of decision analyses to evaluate
its worthiness (23; 24). The sources of disagreement reside in part in the
relatively large uncertainties that still involve the critical input parameters.
This makes ALND a good example for studying the effect of uncertainty on
measuring the value of diagnostic information.
Section 2 presents the solution of multistage decision problems in the presence of parameter uncertainty, discusses the type of Monte Carlo simulation
that is necessary for probabilistic sensitivity analyses, and proposes a set of
summaries and graphical displays to help understanding and communicating
uncertainty about the value of diagnostic information. Section 3 applies the
methodology of Section 2 to evaluating the diagnostic value of ALND.

2
2.1

GENERAL CONCEPTS
Setting

This Section introduces basic concepts and definitions for probabilistic sensitivity analysis of multistage trees, using the context and language of diagnostic testing. For conciseness of notation consider the binary, two–stage case.
A richer two–stage tree, with multiple treatment arms and test outcomes,
is illustrated in the application of Section 3. Figure 1 summarizes the tree
structure and the notation. There are two treatment options: A and B, and
a diagnostic test with binary outcome T, either positive (T+) or negative
(T-). The probability of a positive test result for the cohort under consideration is φ, that is p(T+|φ) = φ. The parameters describing the medical
history of patients after treatment are collectively denoted by the vector θ.
5
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For example, θ could represent the vector of parameters of a survival model
incorporating an effect for treatment. Utilities associated with tree branches
are indicated as in Figure 1, with the notation emphasizing dependence on
the parameters as well as treatment and test outcome.
To simplify the presentation and focus on the diagnostic value of the test,
we assume that performing the test does not have any direct effect on the
utilities of the treatment branches. Most non–invasive tests based on blood
samples or simple tissue extraction are such. Also, we do not consider the
cost of the test explicitly. Under these assumptions, when the parameters φ
and θ are known, utilities for the “no test” branch are related to the utilities
for the test branch by the relationship
−
uRX (θ) = φ u+
RX (θ) + (1 − φ) uRX (θ),

where RX is either A or B. Then we can fold back the tree and compute the
difference in utility between the two arms, which is
+
−
−
∆∗ (φ, θ) = φ max{u+
A (θ), uB (θ)}+(1−φ) max{uA (θ), uB (θ)}−max{uA (θ), uB (θ)}.

(1)
The treatment strategy maximizing utility conditional on knowledge of the
true parameter values will be called true optimal strategy.

2.2

Solving the tree when parameters are unknown

In practice, input parameters φ and θ are often unknown. The set of possible values of φ will typically be the interval (0, 1), while the set of possible
values of θ is more general and will be denoted by Θ. Information about all
unknowns can be represented by a joint probability distribution p(T, φ, θ),
6
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representing the decision analyst’s uncertainty about (T, φ, θ), formed based
on the studies and expert input used in developing the model. This distribution is conveniently factored as
p(T, φ, θ) = p(φ)p(T |φ)p(θ|T, φ).

(2)

The distribution p(T |φ) represents variation in test outcomes over individuals in the cohort, while the distributions p(φ) and p(θ|T, φ) represent the
uncertainty about the model parameters. In a multistage situation it is critical to consider the joint distribution of parameters and test results, as test
results contain information about parameters that needs to be factored in
the analysis to obtain coherent inferences.
When parameters are unknown, decision making at the treatment stage in
the “test” branch proceeds by evaluating expected utilities, averaging over
unknown parameters conditional on the test’s outcome. To this end, we
use the distribution p(φ, θ|T ) = p(φ|T )p(θ|T, φ). The term p(φ|T ) can be
obtained using Bayes rule from the terms p(φ) and p(T |φ) in our original
factorization (2). Specifically, we evaluate
Z 1Z
T
ūRX =
p(φ|T ) p(θ|T, φ) uTRX (θ) dθdφ,
0

(3)

Θ

where RX is either A or B, and T is either + or –. These quantities can be
used to find the treatment strategy that maximizes expected utility for each
test outcome, which will be called current optimal strategy. Unlike the true
optimal strategy, the current optimal strategy is not conditional on knowing
the true parameter values. Rather, it represents the best that can be done,
in terms of expected utility, given the information available at the time of
the decision. It is consistent with the Bayesian principle that decisions at
7
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any point should be made by conditioning on all quantities that are known
and averaging over all those that are unknown.
In the “no test” branch, treatment arms are compared based on expected
utilities, averaging over both parameters and test outcomes. To this end we
use the joint distribution in equation (2). Specifically, we evaluate
ūRX =
=

Z
Z

1
0
1
0

Z X
Z

p(φ)p(T |φ) p(θ|T, φ) uTRX (θ) dθdφ

(4)

Θ

T

Θ

£
¤
−
p(φ) φ p(θ|T +, φ) u+
RX (θ) + (1 − φ) p(θ|T −, φ) uRX (θ) dθdφ.

There are eight possible configurations of solutions for the three decision
nodes at the treatment stage of the tree, depending on the rank order of the
ū’s. For the purpose of our analysis we only need to distinguish two types:
configurations in which the current optimal treatment is always the same,
and configurations in which it varies with the test result. Without losing
generality we can focus on two specific cases:
Case A A is always preferred;
Case B B is preferred if the test is negative and if it is not performed.
In case B the “test” arm is preferred to the “no test” arm if the expected
utility of the “test” arm, call it ū¯, is greater than the expected utility ūB
for the “no test” arm. Computationally, ū¯ is obtained by averaging over all
unknowns, and assuming that the current optimal strategy will be followed
once the treatment node is reached. Therefore
ū¯ =
=

Z
Z

1
0
1
0

Z X
Z

p(φ)p(T |φ) p(θ|T, φ) uTcurrent optimal (θ) dθdφ

(5)

Θ

T

Θ

£
¤
−
p(φ) φ p(θ|T +, φ) u+
A (θ) + (1 − φ) p(θ|T −, φ) uB (θ) dθdφ.
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The expected value of diagnostic information is the difference
Z 1Z
£
¤
+
¯
¯
p(φ) p(θ|T +, φ) φ u+
(θ)
−
u
(θ)
dθdφ.
∆ = ū − ūB =
A
B
0

(6)

Θ

This procedure provides a general way of evaluating the expected value of
diagnostic information in the presence of parameter uncertainty. Comparing
¯ the to the cost of the test gives a cost–effectiveness evaluation.
∆
We assumed that there is no loss of utility from the test. Therefore,
when parameters are known, the information provided by the test may either
increase the average utility in the cohort, if therapy may be changed by the
result or the test, or leave it unchanged if the strategy is also left unchanged.
Mathematically, this is a simple corollary of the fact that ∆ ∗ (φ, θ) cannot,
by construction, be negative. The connection between this mathematical
property of sequential decision making and the value of information has been
part of the foundations of Bayesian decision theory since its inception (9; 12;
25).
When the parameters are not known, it is still the case that the information provided by the test will not decrease the average utility in the cohort,
as long as the distribution of the unknown parameters is correctly updated
upon knowing the results of the test, and the test has no direct effect on
¯ ≥ 0 in
utility. In two–stage binary trees for diagnostic tests, this is true if ∆
¯ = 0.
cases A and B, as all other proceed along the same lines. In case A, ∆
In case B, because therapy A is preferred to therapy B if the test is positive,
we have
+

+

ūA − ūB

=

Z

1
0

Z

Θ

¢
¡
+
p(φ|T +) p(θ|T +, φ) u+
A (θ) − uB (θ) dθdφ > 0.

Substituting p(φ|T +) = p(φ)p(T + |φ)/p(T +) = p(φ)φ/p(T +) and canceling
9
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the term p(T +) gives:
Z

1
0

Z

Θ

¢
¡
+
> 0,
p(φ) φ p(θ|T +, φ) u+
A (θ) − uB (θ) dθdφ

¯ > 0. A similar argument holds for two–stage non–binary trees.
that is ∆

2.3

Monte Carlo Calculations

To solve the tree and implement a probabilistic sensitivity analysis by Monte
Carlo methods, we need to draw M samples
+
−
(φ1 , θ1+ , θ1− ), . . . , (φM , θM
, θM
)

(7)

+
where each φm , m = 1, . . . , M , is drawn from p(φ), each θm
from p(θ|T +, φm ),
−
and each θm
from p(θ|T −, φm ). Samples in (7) do not need to be indepen-

dent. For example, MCMC output after convergence is appropriate. We
assume also that the Monte Carlo sample size M is large enough that all the
expectations necessary for decision analysis are closely approximated by the
corresponding Monte Carlo averages.
Using (7) we can evaluate all ū’s, determine the current optimal strategy,
¯ Specifically,
and evaluate the expected value of diagnostic information ∆.
(3) is evaluated by
M
1 X T
ūRX ≈
u (θT ),
M m=1 RX m
T

(8)

where again RX is either A or B, and T is either + or –. Similarly, for the
no–test arm, (4) is evaluated by
M
¢
1 X¡
−
+
−
ūRX ≈
φ m u+
(θ
)
+
(1
−
φ
)u
(θ
)
m
RX m
RX m .
M m=1

(9)
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In case B the expected value of information (6) is evaluated by
M
M
¢
1 X
1 X ¡ + +
+
+
¯
(θ
)
.
∆≈
∆(φm , θm ) =
φm uA (θm ) − u+
m
B
M m=1
M m=1

(10)

A critical aspect of Monte Carlo approaches to multistage problems is that
multiple (in this case two) sets of samples of θ are necessary, one for each
possible value of the test outcome.
¯ are nonlinear functions of the parameters φ and
Because the ū’s and ∆
θ, it is recommended to solve the tree by evaluating (3), (4), and (6), rather
than using best estimates of φ and θ in a deterministic way.

2.4

Measuring uncertainty about the value of diagnostic information

In a probabilistic sensitivity analysis, it is interesting to study how unknown
parameters affect the difference between the two arms. This difference depends on parameters as well as the treatment strategy. This suggests to
consider two variants: ∆∗ (φ, θ), as defined in (1), assumes that patients in
the “test” arm will be treated according to the true optimal strategy for the
specified φ and θ; and ∆(φ, θ) assumes that patients in the “test” arm will
be treated according to the current optimal strategy, independent of φ and
θ. In case A, ∆ is always 0 for all values φ and θ. In case B, we have
¡
¢
+
∆(φ, θ) = φ u+
(θ)
−
u
(θ)
.
A
B

(11)

The functions ∆ and ∆∗ measure different aspects of the value of diagnostic information as a function of the unknown parameters. Understanding
uncertainty about the value of the diagnostic test requires joint consideration of both. Our suggestions for a basic description of uncertainty is to a)
11
Hosted by The Berkeley Electronic Press

graph the joint distribution of ∆ and ∆∗ , and b) compute the three summary
quantities
PC = P (∆∗ = ∆)
PD = P (∆∗ > 0)
PE = P (∆ > 0).
Naturally, other quantities may also be of interest, but these can provide a
minimal core set.
PC is the probability that the current best and the true best treatment
strategies are the same, or, in other words, that the current treatment strategy is correct. Because the value of the diagnostic test depends on the use
that will be made of the information, it is critical to quantify uncertainty
on its appropriateness. However, this alone is not sufficient. In problems
with multiple options, there are situations in which the current best is only
correct for a small fraction of the simulated values, but the true best is very
similar to it over a broad range of simulated values.
PD is the probability that the test would have diagnostic value if the true
parameter values were known. This quantity reflects the confidence with
which we may say that treatment should be based on this test, no matter
what the true strategy is. Computation of ∆∗ is predicated on the impossible requirement of knowing the true parameter values and underestimates
uncertainty compared to what can be expected in a clinical implementation
of the solution. Therefore, PD is of interest for technology assessment and
research planning rather than clinical decisions to be made in the immediate
future.
12
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PE is the probability that the current best strategy does more good than
harm, or, we could say, is ethical. This is a quantity of direct clinical interest
that measures the confidence with which we can recommend the test and
subsequent therapy decision as a package. It is based solely on the knowledge
currently available. It does not, however, fully answer the question of whether
the test is of value. First, ∆ is identically zero in Case A even though
there may be substantial uncertainty about whether all patients should get
treatment A. Also ∆ could be positive in cases in which the test should not
be used, if the true parameters rank the treatments in the “no test” arm in
the opposite way as the current optimal strategy.

3
3.1

Axillary Lymph Node Dissection in Breast
Cancer
Model Assumptions and Data Sources

This section uses the model structure of Parmigiani and colleagues (24), updating the values of the parameters wherever appropriate, and developing an
assessment of uncertainty for each. Consider a cohort of patients who are 60
years old at diagnosis, have an ER positive primary tumor of size between
0.5 and 1 cm, have a negative clinical exam of the axilla, and have elected
to receive breast conservation therapy. Nodal status information resulting
from ALND is classified in four categories, as described in Figure 2. Also
consider four alternatives for adjuvant therapy: Tamoxifen (T); combination chemotherapy (CT); combination chemotherapy followed by Tamoxifen
(CT+T); and no adjuvant systemic therapy (noRX). All suitable adjuvant
combination chemotherapy regimens are assumed to be equivalent, both in
13
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terms of long–term outcome and effects on quality of life. In practice, differences may exist, but are likely to be small and it is unlikely that the relative
risk reduction would be affected by nodal status.
Solving the tree requires a) a probability distribution of nodal involvement, the vector equivalent of φ, and 2) a probability distribution of survival
times by nodal involvement category, adjuvant therapy, and ALND status,
whose parameters correspond to θ. Data sources were chosen seeking generalizable registry or cohort data for describing the natural history of disease
under standard treatment, and meta–analyses for describing effects of treatments. All inputs are based on primary data or published studies. Probability distributions describing parameter uncertainty reflect inferential uncertainty, with minimal additional subjective input. Real valued parameters are
assigned normal distributions, while probabilities and percentage of risk reduction are assigned beta distributions, and probability vectors are assigned
Dirichlet distributions. Parameters of these distributions were based either
on the reported estimates and standard deviations in the original studies, or
on the estimates obtained directly from source data.
The probability distribution of the number of positive nodes for the given
tumor size, age, and ER status is based on two components. First we estimate probabilities of nodal involvement by category using data from the
NCI SEER cancer registries (26), considering both clinically negative and
clinically positive cases. Estimates of the probabilities of true-negative and
false-negative physical examinations (22) permit conditioning on a clinically
negative axilla, via Bayes’ rule. All parameters estimated using SEER data
were handled using Dirichlet posterior distributions obtained from uniform
14
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priors (27). Because of the very large sample size of the SEER registry,
sensitivity to the choice of priors is minimal in this case.
Survival distributions were also derived by combining several elements.
Survival of patients with positive nodes receiving chemotherapy was estimated using a multivariate Cox regression model with age, ER status, primary tumor size, and nodal involvement as prognostic variables. Patient
level data for this purpose was drawn from four studise conducted within the
CALGB cooperative group. Study numbers are 7581, 8082 and 8541 (28; 29;
30). The simulation relative to the Cox proportional hazard component of
the model, kept the baseline hazard fixed, and drew only the coefficients at
random.
The maximum followup in these CALGB studies is 19 years. Rates beyond 19 years were extrapolated based on a constant hazard rate (set to the
average hazard rate in years 15 to 19). The hazard rate in the first 19 years
is not constant, accounting for greater hazard in the first few months following adjuvant treatment. CALGB trials involved only node–positive women.
To derive a survival curve for node–negative women, the following strategy
was followed: a) For node–negative women with primary tumors larger than
1 cm, results from the EBCTCG overview (15) were used to estimate an
adjustment ratio between node-positive and node negative patients receiving chemotherapy. This ratio is 0.42 for the first 4 years and 0.61 for the
remainder (15). b) For node-negative women with primary tumor smaller
than 1 cm, the results of Rosen and colleagues (31) were used to derive an
adjustment. Mortality from causes other than breast cancer was taken from
US life tables in Splus (32).
15
Hosted by The Berkeley Electronic Press

Survival curves of women undergoing adjuvant therapies other than chemotherapy were derived from the previous analysis together with the results of
EBCTCG overviews (15; 33; 16). The results among node-positive patients
receiving chemotherapy were used as the baseline and then adjusted in accordance with the risk ratios reported in Table 1, to generate survival curves
for all treatment options. We assumed that none of the effects depend on
nodal status (15; 16). Recent evidence from the NSABP B-14 (34) trial also
shows a risk reduction for node-negative patients that is comparable with
that of previously observed node-positive patients.
There are a total of 15 parameters related to the prognostic model that
are being drawn at random. The distributions of the parameters within the
SEER analysis and within the Cox proportional hazard model are dependent,
but the two sets are independent of each other.
Decisions about adjuvant therapy depend on survival benefit as well as
loss of quality of life (QOL). We assumed the QOL adjustments described in
Table 2. While these choices do not reflect every woman’s experience, they
constitute a plausible illustration, consistent with clinical expertise as well
as published estimates (35). To focus on the diagnostic value of ALND, we
use the same QOL adjustment of .995 for the negative impact of both ALND
and XRT.

3.2

Probabilistic sensitivity analysis

Figure 2 shows the decision tree, the expected quality adjusted life years for
each arm, and the expected proportions of ALND outcomes. The “current
best” adjuvant treatment option is to administer Tamoxifen to XRT patients,
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whose nodal status is unknown, and to those ALND patients who are node–
negative, and to administer chemotherapy plus Tamoxifen to ALND patients
who are node–positive. The difference between the expected quality adjusted
life length in the ALND and XRT arms is about 3 days.
There is uncertainty on the correct adjuvant therapy, with P C = .33,
meaning that the current best strategy coincides with the correct one in
about one third of the simulated values. There is also concern on whether
the ALND arm will do better than the XRT arm under the chosen strategy,
with only P E = 52% of simulated parameter sets leading to a better outcome.
Finally the probability that ALND has diagnostic value is P D = 45%.
Overall, uncertainty is substantial, suggesting that the results of the decision analysis, at least for this particular patient type, should not be used
in policy and clinical decision making without explicit consideration of the
uncertainty. From the point of view of an individual patient, the decision
model, which focusses on quantifiable endpoints, may not consider other aspects of the decision, such as the desire to know nodal status even though this
information may not change her course of action. In presence of so much uncertainty about the recommendation emerging from the decision model, these
additional factors may become decisive.
A more detailed representation of uncertainty is provided by the joint
distribution of ∆ and ∆∗ . Both quantities represent the difference between
the average QALYs in the ALND and XRT cohorts, with one critical difference. ∆ is calculated assuming that the adjuvant therapy choices are those
implied by the solution of the tree in Figure 2, while ∆ ∗ is calculated by
rederiving the optimal adjuvant therapy choice for each draw of simulated
17
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parameters. In a two stage–decision such as this, ignorance of the correct
value of the model parameters implies ignorance of the correct decision at
the second stage. This translates into uncertainty about the decision at the
first stage as well. ∆ incorporates this uncertainty, and realistically models
the actual state of knowledge, as parameter values will not be known when
the adjuvant therapy decision needs to be made.
Figure 3 shows the joint distribution of ∆ and ∆∗ , based on 900 simulated
values of the model parameters. Because of the different implications of
different parts of the (∆, ∆∗ ) plane for decision making, it is useful to break
down the distribution into four regions:
∆ < 0, ∆∗ = 0

∆ > 0, ∆∗ = 0

∆ = ∆∗ > 0

∆ > ∆∗ > 0

The test is of no diagnostic value, but under the current
best adjuvant strategy it would lead to a decrement of
utility for the cohort;
The test is of no diagnostic value, but under the current
best adjuvant strategy it would lead to an increment of
utility for the cohort;
The test is of diagnostic value, the current best adjuvant
strategy is correct and administering the test would lead
to an increment of utility for the cohort;
The test is of diagnostic value, the current best adjuvant
strategy is incorrect but still leads to an increment of
utility for the cohort.

Of these regions, three are lines, so distributions of simulated values are
represented in Figure 3 as boxplots of size proportional to the frequencies of
simulated points along the corresponding lines. Overall, the variation of ∆,
attributable to lack of knowledge about the model parameters, far outweighs
the mean value of ∆.
The fraction of points on the diagonal boxplot of Figure 3 is PC. The
fraction of points above zero is PD and that to the right of zero is PE.
18
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Points in ∆ > ∆∗ ≥ 0 are to the right of the diagonal line and correspond
to parameter values for which ALND is of greater value under the current
optimal strategy than it is under the optimal strategy for the given θ. For
example, it is possible that the optimal strategy for the given θ may be to
administer Tamoxifen plus chemotherapy to all nodal status categories, and
therefore to women in the XRT are as well. This means that ∆∗ has no
information component. The current best adjuvant strategy, however, may
have an information advantage. In this case, by administering chemotherapy
to all women, while reducing the difference between the two arms, we would
increase QALYs in both.

4

Discussion

This article presents a solution strategy for multistage decision problems in
presence of uncertainty on input parameters, and proposes a graphical display
and summarization tools for probabilistic sensitivity analysis in multistage
decision trees. For simplicity of exposition, results are reported in terms of
the simplest two–stage binary decision tree. All the development of Section 2
can be straightforwardly rewritten in terms of trees with non–binary nodes.
This situation is in fact illustrated in Section 3. Extensions to more than
two stages can proceed along the same lines conceptually, but rapidly become
much more convoluted.
We focused on the value of diagnostic information and thus assumed
that the test does not have any direct effect on the utilities of the treatment branches. Also, we do not consider the cost of the test explicitly. In
practical application, the test may affect utility in ways that are controlled
19
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by unknown parameters, and cost distributions may also contain unknown
parameters. The approach based on the joint distribution of ∆ and ∆ ∗ is
useful in those circumstances as well. There may not be accumulation of
values along the axes of Figure 3, and some values of ∆∗ may be negative.
The general interpretation of the graph and of the quantities PC, PD and
PE will, however, remain valid.
We provided an application to axillary lymph node dissection in breast
cancer. To keep the focus on measuring the diagnostic value of information about nodal involvement, we did not consider potential direct effects
of ALND on survival, which could occur via differential local control compared to XRT. These effects, however, are not likely to be strong (15), so our
analysis does provide estimates that are of clinical interest. In summary, the
uncertainty analysis presented in this section highlights the following points:
there is substantial uncertainty on whether the course of action chosen by
the decision tree is indeed the best —the probability of that being the case is
about one third. There is also a high (48%) probability that ALND is worse
than XRT for the cohort considered. Finally the probability of the parameter configuraions for which ALND carries valuable diagnostic inforamtion
is P D = 45%. This high level of uncertainty occurs even though the data
sources consist of large and well conducted studies or registries, and emphasizes the importance of systematically accounting for and communicating
uncertainty in decision analysis.
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Table 1: Effects of adjuvant treatments. Entries are mortality reductions for
alternative adjuvant therapies, compared to no adjuvant treatments. Values
in parentheses are the corresponding standard deviations. All values refer to
women older than 50 years of age.
No Rx
T
CT
CT+T

ER+
ER0%
0%
32 (10) %
0%
9 (5) % 17 (6) %
40 (11) % 11 (4) %

Table 2: Illustrative quality adjustment factors, by treatment and month
since the beginning of treatment. Adjustment for either ALND or XRT is
applied for each subsequent year over and above any adjustment for adjuvant
systemic therapy. Quality adjustments for CT+T (not shown in the table)
are obtained using the adjustment factor for C for the first six months and
both adjustments thereafter.
Month:

1–6

7–12

13–24

25–60

>60

No Treatment 1
Tamoxifen
0.99
Chemotherapy 0.6
ALND
.995
XRT
.995

1
0.99
0.9
.995
.995

1
0.99
0.99
.995
.995

1
0.99
0.99
.995
.995

1
1
0.99
0.995
0.995
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Figure 1: Decision tree for the generic binary diagnostic test problem. Leaves
are utilities conditional on knowledge of the model parameters θ.
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Figure 2: Decision tree for the ALND application. Values attached to treatment branches are averages of terminal utilities in QALYs. Values on ALND
outcome branches are average probabilities of nodal involvement categories
“NODES” refers to lymphnodes found to be positive. The current optimal
strategy is T if XRT, and if ALND and no positive nodes are found, and
CT+T otherwise.
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Figure 3: Joint distribution of ∆ and ∆∗ , in days, after 900 simulations
of input parameters. Areas of boxes in boxplots are proportional to the
frequencies of simulated points along the corresponding lines.
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